UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3306140 (State or other jurisdiction of Incorporation or organization) (I.R.S. Employer Identification No.) 84 October Hill Road, Holliston, Massachusetts 01746 (Address of Principal Executive Offices, including zip code) ☐ Transi ...

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $20.5 million, down from $23.1 million in the prior year, but above guidance of $18 million to $20 million due to higher shipments to China [6] - Gross margin decreased to 56.4% from 57.2% in Q2 2024, but was at the high end of guidance [6] - Adjusted operating income improved to $1 million from $800,000 in Q2 2024, and adjusted EBITDA increased to $1.5 million from $1.3 million [7][12] - Year-to-date cash flow from operations was strong at $5.7 million compared to $600,000 in the same period last year [13] Business Line Data and Key Metrics Changes - Revenue in The Americas declined 5.4% sequentially and 11.7% year-over-year, primarily due to budget clarity issues for academic institutions [8] - European revenue increased 9% sequentially, driven by stronger academic shipments, while year-over-year revenues were largely flat [10] - APAC revenue decreased over 25% year-over-year due to tariff-related issues, with orders and shipments halting in April but gradually returning to normal [11] Market Data and Key Metrics Changes - The company’s China business accounted for about 10% of revenue, which nearly went to zero in April but has since returned to a more normal run rate [32] - NIH funding delays are extending academic purchasing cycles, but budgets remain in place, with expectations for improvement into 2026 [19] Company Strategy and Development Direction - The company aims to maintain financial discipline, accelerate product adoption, and strengthen its capital structure through refinancing [17][18] - New product pipeline includes the SOHO telemetry platform and the MeSH MEA organoid platform, which are expected to drive future growth [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the second half of the year, believing that the worst of tariff uncertainties is behind them [19] - The company is focused on stabilizing its core business and restructuring its balance sheet to build sustainable sales and profitability [22] Other Important Information - Net debt decreased to $27.9 million from $32 million, reflecting improved operating cash flow and quarterly principal payments [14] - The company has negotiated amendments to its credit facility, providing additional time to refinance and pay down existing debt [15] Q&A Session Summary Question: What do you expect total debt to be by December 5? - The company expects debt to be around $33 million, continuing to pay down $1 million per quarter [26] Question: What are your thoughts on NIH funding and potential budget changes? - Management noted that academic purchasing cycles have been extended, but budgets remain in place, which could benefit the business if conditions improve in 2026 [30] Question: What is your current exposure to China and how did it perform in the quarter? - The China business is about 10% of revenue, which saw a significant decline in April but has returned to normal levels [32]

Financial Performance - Q2 2025 revenue was $20.5 million, compared to $23.1 million in Q2 2024[6] - Gross margin in Q2 2025 was 56.4%, compared to 57.2% in Q2 2024[6] - Adjusted EBITDA for Q2 2025 was $1.5 million, compared to $1.3 million in Q2 2024[6] - Q3 2025 revenue is projected to be in the range of $19 million to $21 million[16] - Q3 2025 gross margin is projected to be in the range of 56% to 58%[16] Regional Performance - APAC region experienced a 25.4% year-over-year decrease in Q2 2025, but with a 1.1% increase from F/X[7] - EMEA region was relatively flat, with a 0.3% year-over-year decrease in Q2 2025, but with a 5.0% increase from F/X[7] - US Pre-Clinical declined 11.7% year-over-year in Q2 2025[7] Strategic Focus - The company is prioritizing stabilizing the core business and restructuring the balance sheet to build sustainable sales and profitability[19] - The company is positioning the business for renewed growth and margin expansion in 2026 and beyond[19] - The company is focused on accelerating product adoption by leveraging a strong and innovative pipeline[19]

Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2025 Financial Results HOLLISTON, Mass., August 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2025. "We made solid progress in the second quarter exceeding our revenue guidance. In my short time as CEO, I have already seen first- hand the dedication of our team. The fundamentals of the business remain intact with attractive mar ...

HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast ...

Leadership Transition - Harvard Bioscience announced a CEO succession plan with John Duke set to become President & CEO on July 28, 2025, following Jim Green's retirement after over 8 years as Chairman and 6 years as President & CEO [1][3] - John Duke has a strong background, previously serving as CEO of Plastic Molding Technology with approximately 20% annual revenue growth, and has over 20 years of experience at Corning Incorporated [2][3] Board Appointments - The company appointed Rob Gagnon and Seth Benson to the Board of Directors effective July 16, 2025 [3][6] - Rob Gagnon has over 20 years of experience in global finance operations in the life sciences industry and previously served as CFO of Harvard Bioscience from 2013-2018 [4] - Seth Benson has significant leadership experience in finance and technology, currently serving as CFO of Nuclera Ltd [5] Financial Performance - Harvard Bioscience expects second quarter 2025 revenue to be $20.4 million and has reiterated its gross margin guidance of 55% to 57% for the same period [7][8]

Core Insights - Harvard Bioscience, Inc. has appointed John Duke to its board of directors, effective June 2, 2025, and he will also serve on the audit and nominating and governance committees [1][2] - Katherine Eade has been named Lead Independent Director of the Company's board of directors [1] - Thomas Loewald has retired from the board after serving since October 2017 [3] Company Overview - Harvard Bioscience, Inc. is a leading developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bio-production, and preclinical testing for pharmaceutical development [4] - The Company serves a diverse customer base, including academic institutions, government laboratories, and leading pharmaceutical and biotechnology organizations, with operations in the United States, Europe, and China [4]

Financial Performance - Revenues decreased by $2.7 million, or 11.2%, to $21.8 million for the three months ended March 31, 2025, compared to $24.5 million for the same period in 2024[80]. - Gross profit decreased by $2.6 million, or 17.5%, to $12.2 million, with a gross margin of 56.0% for the three months ended March 31, 2025, down from 60.3% in 2024[81]. - Cash provided by operating activities increased to $3.0 million for the three months ended March 31, 2025, compared to $1.4 million in the same period of 2024, reflecting a growth of approximately 113%[96]. - Cash used in investing activities rose to $0.7 million in Q1 2025 from $0.2 million in Q1 2024, primarily due to capital expenditures for manufacturing and software development[97]. - Cash used in financing activities was $1.2 million for the three months ended March 31, 2025, compared to $1.1 million in the same period of 2024, with $1.0 million allocated to debt repayments[98]. Expenses - Sales and marketing expenses decreased by $0.9 million, or 15.8%, to $5.0 million for the three months ended March 31, 2025[82]. - General and administrative expenses decreased by $0.8 million, or 13.0%, to $5.2 million for the three months ended March 31, 2025[83]. - Research and development expenses decreased by $0.6 million, or 19.5%, to $2.3 million for the three months ended March 31, 2025[84]. Cash and Liquidity - Cash and cash equivalents increased to $5.5 million as of March 31, 2025, compared to $4.1 million as of December 31, 2024[91]. - Cash and cash equivalents increased by $1.4 million in Q1 2025, contrasting with a decrease of $28,000 in Q1 2024[96]. - The company experienced cash inflows from accounts receivable of $0.7 million and inventories of $1.3 million in Q1 2025, contributing to the positive cash flow from operations[96]. - Borrowings outstanding were $36.4 million as of March 31, 2025, down from $37.4 million as of December 31, 2024[91]. - There is substantial doubt about the company's ability to continue as a going concern unless alternative sources of capital are accessed or repayment dates under the Credit Agreement are extended[95]. Impairments and Losses - A non-cash goodwill impairment charge of $48.0 million was recorded during the three months ended March 31, 2025[86]. - Losses associated with the translation of foreign equity into U.S. dollars were $1.3 million for Q1 2025, compared to $0.8 million in Q1 2024, indicating an increase of 62.5%[100]. - Currency exchange rate fluctuations contributed to a loss of $0.2 million in Q1 2025, while such fluctuations were not significant in Q1 2024[100]. Foreign Currency Impact - The effect of foreign currency exchange rates resulted in a $0.1 million unfavorable impact on revenues and a $0.1 million favorable impact on expenses during Q1 2025[100]. - Recent accounting pronouncements impacting the business are detailed in the financial statements[102]. Accounting Policies - There have been no material changes to the critical accounting policies underlying the financial statements[101].

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $21.8 million, down from $24.5 million in the prior year, aligning with the higher end of guidance [7][11] - Gross margin decreased to 56% from 60.3% in Q1 2024 [8][15] - Operating loss was $49.7 million compared to a loss of $2.3 million in Q1 2024, primarily due to a goodwill impairment charge [9][10] - Adjusted EBITDA was $800,000, down from $1.6 million in the previous year [10][16] - Cash flow from operations improved to $3 million from $1.4 million in Q1 2024 [17] Business Line Data and Key Metrics Changes - Revenue in The Americas declined 5.4% sequentially and 9.4% year-over-year [12] - European revenue decreased 29% sequentially and 9% year-over-year [13] - APAC revenue increased 6.6% sequentially but was down 17% compared to the prior year [14] Market Data and Key Metrics Changes - The Americas faced slow sales due to budget clarity issues in academic and NIH funding [12] - Europe experienced a decline in cellular and molecular sales, although growth was noted in cell-based testing [13] - APAC market showed signs of improvement but anticipated challenges due to tariff announcements [14] Company Strategy and Development Direction - The company is focusing on expanding adoption of new products while continuing to lower costs, with an expected reduction in operating expenses by an additional $1 million per quarter starting Q2 2025 [26] - New product introductions are categorized into base business, electroporation and bioproduction systems, and MEA/organoid systems, with a strong pipeline of industrial and academic customers [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns about NIH funding and the impact of tariffs on revenue, particularly in China, which constitutes about 10% of total revenue [54] - The company expects Q2 revenue to be in the range of $18 million to $20 million, with gross margin projected between 55% and 57% [26] Other Important Information - A non-cash goodwill impairment charge of $48 million was recorded due to a decrease in market capitalization [10][30] - The company is in the process of refinancing its debt facility, with indications of interest from multiple providers [18][46] Q&A Session Summary Question: Can you elaborate on the impairment charge? - Management explained that the impairment was due to a drop in market capitalization, necessitating a reassessment of goodwill using a DCF approach, leading to a $48 million non-cash charge [30] Question: What about the bioproduction business and CAR T therapy? - Management confirmed that the BTX system is being used by a domestic customer for CAR T therapy development, indicating strong traction in the bioproduction space [31][32] Question: How is the MEA product line performing amid NIH funding uncertainties? - Management noted strong interest in the MEA product line, particularly from academic researchers, despite a slowdown in purchasing processes due to NIH budget cuts [34][35] Question: Will BTX technology compete with MaxSight? - Management indicated that while they could potentially compete, their strategy focuses on early adopters and a razor-razor blade model rather than high-volume applications [40][41] Question: Will animal testing slow down? - Management affirmed that animal testing will continue to be necessary for safety and efficacy verification, although organoids may reduce the need for large animal populations in early testing [43][45] Question: What are the refinancing terms? - Management stated that the refinancing will be more expensive than commercial debt, with a term likely around four to five years [46][49]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $21.8 million, down from $24.5 million in Q1 2024, aligning with the higher end of guidance [7][10] - Gross margin decreased to 56% from 60.3% in the previous year [8][14] - Operating loss was $49.7 million compared to a loss of $2.3 million in Q1 2024, primarily due to a goodwill impairment charge of $48 million [8][10] - Adjusted EBITDA was $800,000, down from $1.6 million in Q1 2024 [15] - Cash flow from operations improved to $3 million from $1.4 million in the prior year [16] Business Line Data and Key Metrics Changes - Revenue in The Americas declined 9.4% year-over-year and 5.4% sequentially [11] - European revenue decreased 29% sequentially and 9% year-over-year [12] - APAC revenue increased 6.6% sequentially but was down 17% compared to the prior year [13] Market Data and Key Metrics Changes - The Americas faced a slowdown attributed to budget clarity issues for academic and NIH funding [11] - European sales were impacted by a lack of seasonal bump and lower CRO sales [12] - APAC market showed slight sequential growth but anticipated challenges due to tariff announcements [13] Company Strategy and Development Direction - Focus on expanding adoption of new products while reducing costs, with an expected reduction in operating expenses by an additional $1 million per quarter starting Q2 2025 [25] - New product introductions include the SOHO telemetry devices and VivaMARS system, targeting both academic and industrial customers [19][20] - Emphasis on bioproduction applications and exploring partnerships for CAR T therapy production [21][31] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns over NIH funding and the impact of tariffs on revenue, particularly in China [25][53] - Positive outlook on the adoption of organoid systems due to government policy changes encouraging alternative testing methods [24][34] - Anticipated Q2 revenue guidance is between $18 million to $20 million, with gross margin expected to be in the 55% to 57% range [25] Other Important Information - Goodwill impairment charge of $48 million was recorded due to a decrease in market capitalization [10][29] - Net debt decreased to $30.8 million, reflecting improved cash flow management [16] Q&A Session Summary Question: Can you elaborate on the impairment charge? - Management explained that the impairment was due to a drop in market cap, necessitating a reassessment of goodwill, leading to a non-cash charge of $48 million [29] Question: What about the bioproduction business and CAR T therapy? - Management confirmed that the BTX system is being adopted by a domestic biotech for CAR T therapy production, indicating strong traction in the market [31] Question: How is the MEA product line performing amid NIH funding uncertainties? - Management noted strong interest in the MEA product line, particularly from academic researchers, despite a slowdown in purchasing processes due to NIH staffing changes [34][45] Question: What are the refinancing plans? - Management indicated that refinancing will be more expensive than commercial rates, with terms likely spanning four to five years [46][48]